by Ekrem Duman | Aug 4, 2026 | Chemicals, Pharma & Life Sciences, Startup
⚡ TL;DRBoehringer Ingelheim is among the largest pharmaceutical companies in the world that has never listed, funding multi-billion research programmes entirely from its own cash flow under family ownership. Its animal health division and its metabolic and...
by Ekrem Duman | Aug 4, 2026 | Chemicals, Pharma & Life Sciences, Startup
⚡ TL;DRMerck KGaA is over three hundred and fifty years old, listed on the stock exchange, and still controlled by the founding family through a partnership structure that gives family partners governance rights no ordinary shareholder can override. It is the...
by Ekrem Duman | Aug 4, 2026 | Chemicals, Pharma & Life Sciences, Startup
⚡ TL;DRBioNTech spent a decade developing messenger RNA technology for cancer with almost no revenue, then delivered a vaccine at unprecedented speed and generated tens of billions of euros in eighteen months. The interesting question is not how it succeeded...
by Ekrem Duman | Aug 4, 2026 | Chemicals, Pharma & Life Sciences, Startup
⚡ TL;DRBayer paid sixty-three billion dollars for Monsanto in 2018 and inherited a litigation liability that destroyed most of its market value, forced a dividend cut and consumed a decade of management attention. In June 2026 the United States Supreme Court...
by Ekrem Duman | Aug 4, 2026 | Chemicals, Pharma & Life Sciences, Startup
⚡ TL;DRBASF built the most integrated chemical site in the world at Ludwigshafen, where the output of one plant is the input of the next across hundreds of processes. That Verbund model was unbeatable when European gas was cheap. Since 2022 it has been a...
